Review
British Journal of Cancer (2009) 100, 228–232. doi:10.1038/sj.bjc.6604801 www.bjcancer.com
Published online 25 November 2008
The spliceosome as target for anticancer treatment
R J van Alphen1, E A C Wiemer1, H Burger1 and F A L M Eskens1
1Department of Medical Oncology, Erasmus University Medical Centre, PO Box 2040, Rotterdam 3000 CA, the Netherlands
Correspondence: Dr FALM Eskens, E-mail: f.eskens@erasmusmc.nl
Received 4 August 2008; Revised 30 October 2008; Accepted 4 November 2008; Published online 25 November 2008.
Abstract
The spliceosome is a ribonucleoprotein complex involved in RNA splicing, that is, the removal of non-coding introns from precursor messenger RNA. (Alternative) Splicing events may play an essential role in tumourigenesis. The recent discovery that the spliceosome is a target for novel compounds with anticancer activity opens up new therapeutic avenues.
Keywords:
spliceosome, alternative splicing, planiedolide, E-7107, spliceostatin A
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
NEWS AND VIEWS
Nature Chemical Biology News and Views (01 Sep 2007)
Nature Chemical Biology News and Views (01 Dec 2008)
RESEARCH
Splicing factor SF3b as a target of the antitumor natural product pladienolide
Nature Chemical Biology Letter (01 Sep 2007)
Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA
Nature Chemical Biology Article (01 Sep 2007)
